Is Ultragenyx Pharmaceutical Inc. (RARE) a Buy, Sell, or Hold?
NASDAQ : RARE
Ultragenyx Pharmaceutical Inc. — Analyst Ratings
$25.67 USD
$0.65 (2.6%)
- Volume
- 601.44K
- Average Volume
- 2.2M
- Market Capitalization
- $2.53B
- P/E Ratio
- -4.20
- Dividend Yield
- 0.00%
- Price Target
- $41.50
- Year High
- $39.89
- Year Low
- $18.29
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $2.02
Analyst Consensus Summary
Consensus Rating
Sell
33 Analysts
Rating Score
2/5
Recommendation Strength
Upside/Downside
-38.1%
vs Current Price
Price Target
$41.50
Average TargetPrice Target Range
Lowest Target
$30.00
-14.4% DOWNSIDE
Average Target
$41.50
Median Estimate
Highest Target
$67.00
-61.7% DOWNSIDEAnalyst Breakdown
Overall Consensus: Buy | Total Analysts: 33
| Strong Buy | Buy | Hold | Sell | Strong Sell |
|---|---|---|---|---|
| 0 | 26 | 6 | 1 | 0 |
Analyst Ratings (Detailed)
| Analyst Company | Analyst Name | Price Target | Price When Posted | Date | Upside/Downside |
|---|---|---|---|---|---|
| Barclays | Eliana Merle | $43 | $24.53 | 2026-04-29 05:43 AM | 75.3% |
| Leerink Partners | Joseph Schwartz | $60 | $21.3618 | 2026-03-12 10:39 AM | 180.9% |
| Evercore ISI | Gavin Clark-Gartner | $34 | $20.14 | 2026-02-18 08:17 AM | 68.8% |